Novel small-molecule therapy of Hodgkin lymphoma (Q36817140)

16 August 2017

1 reference

title

Novel small-molecule therapy of Hodgkin lymphoma (English)

1 reference

16 August 2017

Daniela Buglio

1

1 reference

PubMed ID

17492936

16 August 2017

Georgios Georgakis

series ordinal

2

1 reference

PubMed ID

17492936

16 August 2017

Anas Younes

series ordinal

3

1 reference

16 August 2017

1 May 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

5

1 reference

16 August 2017

735-740

1 reference

From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

State-of-the-art therapeutics: Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Hodgkin's lymphoma: molecular targets and novel treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

PTEN: from pathology to biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Expression of Bcl-2 family members and presence of Epstein-Barr virus in the regulation of cell growth and death in classical Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Pharmacological manipulation of Bcl-2 family members to control cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

21 January 2018

Heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Heat shock protein 90: a unique chemotherapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Histone deacetylase inhibitors and cancer: from cell biology to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.735

21 January 2018

Identifiers

DOI

10.1586/14737140.7.5.735

1 reference

16 August 2017

1 reference

PubMed ID

17492936